Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

It's been a sad week for Vertex, Inc. ( NASDAQ:VERX ), who've watched their investment drop 14% to US$20.08 in the ...

The stock of niche financial software company Vertex (NASDAQ: VERX) didn't get a very good start to the trading week at all.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know.

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...

Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion, gaining access to povetacicept, a potential treatment for IgA nephropathy and up to seven additional indications.

Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 11 trades. If we ...

Vertex (NASDAQ: VERX) delivered a split result this morning that left investors parsing mixed signals. The tax technology ...

Vertex Pharmaceuticals' core business is still firing on all cylinders. The biotech is expanding into other areas and diversifying its portfolio. Shares of Vertex look too attractive to pass up right ...